OUHSC Research News – Monday, June 20, 2022

 

Notices and Reminders

SoonerTrack II Update

The Office of Research Administration (ORA) anticipates that the SoonerTrack II system will go live on July 11, 2022, replacing the SoonerTrack I system. ORA continues work on development and configuration of SoonerTrack II. User Acceptance Testing (UAT) of SoonerTrack II with departmental testers ended on June 17, 2022. We are grateful for their time and effort in supporting us with system testing. Please check your current SoonerTrack tickets for any outstanding statuses that need to be completed/withdrawn prior to the go-live date. If you have any questions, please contact soonertrackhelpdesk@ouhsc.edu.

SoonerTrack II Training Opportunities

Pre-scheduled SoonerTrack II training sessions are available at the following dates and times. All sessions are the same, so register for the one that best fits your schedule. Additional dates will be provided as needed (These sessions will be conducted via Zoom).  

1. Tuesday, Jun 28, 2022, 10:30 AM - 11:30 AM

Register here  

2. Wednesday, Jun 29, 2022, 2:30 PM - 3:30 PM

Register here

3. Wednesday, Jul 6, 2022, 9:00 AM - 10:00 AM

Register here

4. Thursday, Jul 7, 2022, 2:00 PM - 3:00 PM

Register here

5. Wednesday, Jul 13, 2022, 10:30 AM - 11:30 AM

Register here

6. Wednesday, Jul 20, 2022, 1:30 PM - 2:30 PM

Register here

 

New Process for Investigators Providing OU Health Patient Data to Outside Entities

If you are providing OU Health patient data as part of your research to any external entity, CRIOC (Clinical Research Informatics Oversight Committee) approval is required. CRIOC composed of legal, compliance, privacy, security, and research officials from the OU Health and Health Sciences Center (HSC) administrations.  CRIOC meets at least once per month to review projects requesting to repurpose OU Health data for research.  The committee is tasked with weighing any institutional liabilities impacted by usage and exchanges of these data.  To enter the review queue, please complete this form: https://redcap.link/crioc_review.  You can contact Melisa Tunley (melisa-tunley@ouhsc.edu) for any questions you have about the form or the review processing steps.

 

NIH Reminder: Action Required for In-Progress RPPR Budget Forms By or Before June 22 (NIH Extramural Nexus) Recipients with in-progress RPPR budget forms, remember to submit by June 22 to avoid having to redo the budget forms. The June 23 release of the RPPR module will include updates to the FORMS-G budget forms. See NOT-OD-22-130 for details.  RPPRs submitted on or before June 22 will reflect the FORMS-F budget forms. Due dates for submission of the RPPR remain unchanged. 

See https://grants.nih.gov/grants/rppr/index.htm.  https://nexus.od.nih.gov/all/2022/06/02/reminder-action-required-for-in-progress-rppr-budget-forms-by-or-before-june-22/

 

Updated RPPR Instruction Guide Available

An updated RPPR Instruction Guide is now available. The instruction guide reflects changes associated with recently issued guide notices on Other Support and Biosketch format pages, human subjects, Trainee Diversity Report and NRSA childcare costs reporting (see NOT-OD-22-130 for details).  Note that a final RPPR Instruction Guide will be published on June 23 to reflect the revised screenshots accompanying the new look and feel of the RPPR module.  

 

NIH Disclosures Guidance

As a reminder, NIH policy now requires applicants and awardees to disclose “all resources made available to a researcher in support of and/or related to all of their research endeavors, regardless of whether or not they have monetary value and regardless of whether they are based at the institution the researcher identifies for the current grant.”  Further details on what needs to be disclosed can be found on Notice NOT-OD-19-114.

If you are not sure whether a particular activity should be reported in the biosketch, other support, or annual project reports, check out  NIH Disclosures Table. This table provides a list of various activities and when they need to be disclosed.

 

ORA Notice: CRIOC (Clinical Research Informatics Oversight Committee) Approval

ORA has stablished a process for actively managing requests to share health data with third parties. Regardless of whether or not human subjects are involved in research project, Principal Investigators (PIs) are required to answer the following questions. We are asking these questions manually until SoonerTrack II is up and running with the questions as part of the request form.

Please note that if OU Health patient data is being used, we cannot proceed with posting the Notice of Award (NOA) until the CRIOC approval is received.

• Are you sharing any data that contains Protected Health Information (PHI), Personally Identifiable Information (PII), Limited Data Set (LDS), De-Identified, or Other?
  • If no, no further information necessary.
  • If yes, answer the following:

• What type of data (please state PHI, PII, LDS, De-Identified, or Other; may be a combination)?
• Does the data being shared come from OU Health patient data?
• With respect to the data being shared, is OUHSC the Provider, Recipient, or Mutual?
• Finally, please provide a description of the data being shared

 

 

Workshops and Seminars

Harold Hamm Diabetes Center (HHDC) - Please mark your calendar for the 19th Annual Harold Hamm Diabetes Center Research Symposium. This in-person event will be held on Friday, November 11, 2022 at the Samis Education Center at Children’s Hospital in Oklahoma City. Deadline for abstracts will be announced in the coming weeks. Additional details will be posted on be posted here. Questions? Please email: Katie-Hoefling@ouhsc.edu

 

OUHSC Funding Opportunities

Office of Technology Commercialization presents the following opportunities for researchers to engage with industry (click here for more information, or email otc@ou.edu or gina-mcmillen@ouhsc.edu).  

• A multinational biopharmaceutical company is seeking approaches to treat primary and secondary rheumatology diseases.  Small molecule, antibody and gene therapy approaches with potential for “reset” of the immune system that include long term/extended disease and drug-free remission and infrequent dosing intervals are of highest interest.  Out of scope: antigen-specific peptide immunotherapy/tolerance, regulatory T cell based approaches, cell based therapy, drug repurposing and immunosuppressants /immunotherapy.  Submission entails a 1-pg non-confidential summary of technology with optional supplemental information.  (deadline 06/22)
• BASF is seeking biodegradable micro-encapsulation technologies for agricultural active ingredients.  Of particular interest are non-microplastic core/shell particles to encapsulate hydrophobic active ingredients.  Polymers from natural sources/resources are preferred. Submission entails a 1-pg non-confidential summary of technology with optional supplemental information.  (deadline 06/22)
• The Sustainable Materials Division at Faurecia, a tier-one automotive supplier, is seeking approaches for developing low carbon footprint carbon fibers for H2 storage tanks to decrease CO2 emission factors. All types of carbon fiber precursors are of interest; solutions to optimize the carbon fiber production process and solutions to produce a substitute of carbon fiber with similar mechanical properties are of particular interest.  Submission entails a 1-pg non-confidential summary of technology with optional supplemental information.  (deadline 07/05)

 

 NIH Notices  

• Updated Policy on SBIR/STTR Organization Eligibility in Cases of Legal Action that Changes Small Business Status
  (NOT-OD-22-143)
• Notice of Joint NSF/NIGMS Initiative to Support Research at the Interface of the Biological and Mathematical Sciences
  (NOT-GM-22-039)
• Correction to NOT-HG-22-014: Solicitation of Nominations for the 2022 National Human Genome Research Institutes Outstanding Award for Enhancing Diversity, Equity, Inclusion, and Accessibility in the Genomics Workforce
  (NOT-HG-22-029)
• Notice of NHLBI Participation in NOT-OD-22-140 "Notice of Special Interest: Administrative Supplement for Research Efforts that Illuminate Fundamental Processes Underlying Behavior Change, Maintenance, and Adherence" (Admin Supp Clinical Trial Optional)
  (NOT-HL-22-029)
• NIH Announces the Open Period of FY 2023 Helium-3 Requests for Medical Research
  (NOT-HL-22-032)
• Notice of Correction to NOT-OD-22-109 - Inviting Comments and Suggestions on the Development of a Prize Competition for Institutional Excellence in Diversity, Equity, Inclusion, and Accessibility.
  (NOT-OD-22-147)
• Notice of Correction to Salary Amounts for RFA-AG-23-016, "Transition to Aging Research for Predoctoral Students (F99/K00 Clinical Trial Not Allowed)
  (NOT-AG-22-026)
• Notice of Correction to RFA-CA-22-022, "Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)"
  (NOT-CA-22-090)
• Notice to Extend Expiration Date for PAR-20-277: Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 Clinical Trial Not Allowed)
  (NOT-CA-22-093)
• Notice of NCI's Participation in Notice of Special Interest: Administrative Supplement for Research Efforts that Illuminate Fundamental Processes Underlying Behavior Change, Maintenance, and Adherence (Admin Supp Clinical Trial Optional)
  (NOT-CA-22-101)
• Notice of NIDA's Participation in NOT-EB-22-001, " Notice of Intent to Publish a Funding Opportunity Announcement for Point-of-Care Technologies Research Network Centers (U54 Clinical Trial Optional)"
  (NOT-DA-22-069)
• Notice of Change of Application Due Date and Application Types Allowed for RFA-ES-22-004 "SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed)"
  (NOT-ES-22-012)
• Notice of Expiration of RFA-HL-21-013 "Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required)"
  (NOT-HL-22-031)
• Notice to Extend RFA-MH-21-180, BRAIN Initiative: Reagent Resources for Brain Cell Type-Specific Access and Manipulation to Broaden Distribution of Enabling Technologies for Neuroscience (U24 Clinical Trial Not Allowed)
  (NOT-MH-22-250)
• Notice of NINR Participation in NOT-OD-22-140, Notice of Special Interest (NOSI): Administrative Supplement for Research Efforts that Illuminate Fundamental Processes Underlying Behavior Change, Maintenance, and Adherence (Admin Supp)
  (NOT-NR-22-014)
• Notice of Corrected Application Forms and Extended Receipt Date for PAR-22-076 "Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)"
  (NOT-NS-22-110)
• Notice of Additional Information for Funding Opportunity RFA-RM-22-020, NIH Directors Transformative Research Awards (R01 Clinical Trial Optional)
  (NOT-RM-22-017)
• Notice of Change to PD(s/PI(s) Eligibility Requirements and Addition of Letter of Intent Deadline for PAR-19-362 Planning Grant for Global Infectious Disease Research Training Program (D71 - Clinical Trials Not Allowed)
  (NOT-TW-22-004)
• Notice of Intent to Publish a Funding Opportunity Announcement for The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 Clinical Trial Not Allowed)
  (NOT-CA-22-088)
• Notice of Intent to Publish a Funding Opportunity Announcement for NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
  (NOT-CA-22-094)
• Notice of Intent to Publish a Funding Opportunity Announcement for Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed)
  (NOT-DA-22-070)
• Notice of Intent to Publish a Funding Opportunity Announcement for Centers for Oceans and Human Health 4: Impacts of Climate Change on Oceans and Great Lakes (COHH4) (P01 Clinal Trial Optional)
  (NOT-ES-22-011)
• Notice of Intent to Publish the Reissuance of RFA-OD-20-008, Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Not Allowed)
  (NOT-OD-22-081)
• Notice of Intent to Publish the Reissuance of RFA-OD-20-011, Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Required)
  (NOT-OD-22-082)
• Notice of Intent to Publish the Reissuance of RFA-OD-20-009, Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Not Allowed)
  (NOT-OD-22-083)
• Notice of Intent to Publish the Reissuance of RFA-OD-20-010, Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Required)
  (NOT-OD-22-084)
• Notice of Special Interest (NOSI): Research to Support Regulatory Science on Infant Formula
  (NOT-HD-22-016)
• Notice of Special Interest (NOSI): Preventive Interventions to Address Cardiometabolic Risk Factors in Populations that Experience Health Disparities
  (NOT-OD-22-154)
   

NOTE: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted).  The letters of intent will be reviewed and a single application will be chosen for submission from the University.

 

NIH Funding Opportunities

• Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)
  (PAR-22-164)
  Application Receipt Date(s): Multiple dates, see announcement.
• Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)
  (PAR-22-165)
  Application Receipt Date(s): Multiple dates, see announcement.
• Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional)
  (PAR-22-198)
  Application Receipt Date(s): September 07, 2025
• Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional)
  (PAR-22-199)
  Application Receipt Date(s): September 07, 2025
• Network for Personalization of Diagnostic Tests for Alzheimers Disease (AD) and Alzheimers Disease-Related Dementias (ADRD) in Older Adults with Multiple Chronic Conditions (MCCs) (U24 Clinical Trial Optional)
  (RFA-AG-23-032)
  Application Receipt Date(s): October 17, 2022
• Limited Competition: A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research (U24 Clinical Trial Not Allowed)
  (RFA-CA-22-026)
  Application Receipt Date(s): September 15, 2022
• Registry of Medical Cannabis Use and Health Outcomes (UM1 - Clinical Trial Optional)
  (RFA-DA-23-011)
  Application Receipt Date(s): November 15, 2022
• Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 Clinical Trial Not Allowed)
  (RFA-DA-23-052)
  Application Receipt Date(s): August 10, 2022
• Pragmatic Clinical Trials in Community Settings to Decrease or Prevent VCID Outcomes, Including in Populations that Experience Health Disparities (U01 Clinical Trial Required)
  (RFA-NS-23-001)
  Application Receipt Date(s): September 15, 2022

 

Other Funding Opportunities

The International Center for Responsible Gaming - Small Grants for Research on Lottery Gambling

Description: The International Center for Responsible Gaming and the Hoosier Lottery are collaborating on a special initiative to encourage research on responsible gambling as it relates to lottery gambling. Research projects may include but are not limited to: 

• Stand-alone research projects or a pilot project; 
• Preliminary research in preparation for a large research project, such as a comprehensive literature review, or instrument development and testing; and 
• Research tasks subsequent to a full research project, such as follow-up testing. 

Applicants may request up to $25,000 in direct costs and $5,000 in Facilities and Administration costs

Application Deadline: September 1, 2022

Link to Full Announcement: https://www.icrg.org/research-center/apply-icrg-funding

 

The Mark Foundation for Cancer Research - Endeavor Award and Informational Webinars

Description: The Mark Foundation Endeavor Awards support teams of scientists with diverse areas of expertise to address urgent problems in cancer research. The Endeavor Award program enables teams of three or more investigators to tackle challenges in cancer research that are too large for any single lab to address alone. Endeavor Awards are $3 million grants disbursed over a three-year term.

Informational Webinars: Endeavor Award website

LOI Submission Deadline: July 13, 2022

Link to Full Announcement: https://mailchi.mp/467458b9d14a/our-first-ever-newsletter-13500801?e=2d3e7329ff

 

The Oklahoma Center for the Advancement of Science and Technology (OCAST)  Notice of Funding Opportunity Announcements. OCAST has published a list of Funding Opportunity Announcements for FY 2022. The guidelines for 2022 have not been released yet. Next application submission period opens on August 15, 2022 and closes September 26, 2022. More information about the funding opportunity announcements and additional resources are available here: https://oklahoma.gov/ocast/ogx-overview/funding-opportunities.html.

 

The Cystic Fibrosis Foundation (CFF): Biological Basis for CF-Related Diabetes Program

Description: The intent of this request for applications is to solicit and fund projects that will improve our understanding of the biological basis for the development and progression of cystic fibrosis-related diabetes as well as to identify potential novel therapeutic strategies to manage and treat the disease. 

Application deadline: August 2, 2022

Link to Full Announcement: https://www.cff.org/researchers/biological-basis-cf-related-diabetes-program

 

The Cystic Fibrosis Foundation (CFF): Path to a Cure -- Collaborative Research Grant

Description: Path to a Cure: Collaborative Research Grants are intended to facilitate research that will contribute to the development of new therapies or therapeutic strategies to treat CF, with an emphasis on advancing CFTR gene repair and replacement approaches. Collaborations that bring new investigators and technologies into the CF research community will be given highest priority. Proposals must include preliminary data to justify support from the Cystic Fibrosis Foundation.

Application deadline: July 14, 2022

Link to Full Announcement: https://www.cff.org/researchers/path-cure-collaborative-research-grant

 

2022 Michelson Prizes: Next Generation Grants

Description: Next Generation Grants are $150,000 research grants given annually to support promising researchers who are applying disruptive concepts and inventive processes to advance human immunology, vaccine discovery, and immunotherapy research for major global diseases. The committee will be looking for research aimed at tackling the current roadblocks that exist in human vaccine development and expanding our limited understanding of key immune processes that are fundamental to successful vaccine and immunotherapy development. The Michelson Prizes are awarding research that is highly innovative and impactful, with the potential to be applied across many diseases.

Application deadline: June 26, 2022

Link to Full Announcement: https://www.humanvaccinesproject.org/michelson-prizes/

 

DoD FY22 Kidney Cancer Research Program (KCRP)

• Concept Award (CA)
• Postdoctoral and Clinical Fellowship Award (PCFA)

Pre-Application (Letter of Intent): June 23, 2022
Application: July 14, 2022

Link to Full Announcement: https://cdmrp.army.mil/funding/kcrp

 

DoD FY22 Breast Cancer Research Program (BCRP)

• Breakthrough Award Levels 1 and 2 II (BTA12-2)
• Era of Hope Scholar Award II (EOHS-2)

Pre-Application (Letter of Intent): September 22, 2022
Application: October 6, 2022 

• Breakthrough Award Level 3 II (BTA3-2)
• Breakthrough Award Level 4 II (BTA4-2)
• Innovator Award II (INNOV-2)
• Transformative Breast Cancer Consortium Award II (TBCCA-2)

Pre-Application (Preproposal): August 3, 2022
Invited Application: November 2, 2022

Link to Full Announcement: https://cdmrp.army.mil/funding/bcrp

 

DoD FY22 Melanoma Research Program (MRP)

• Idea Award (IA)

Pre-Application (Preproposal): July 8, 2022
Application: October 5, 2022

• Melanoma Academy Scholar Award (MASA)
• Mid-Career Accelerator Award (MCAA)
• Team Science Award (TSA)
• Focused Program Award – Rare Melanomas (FPA)

Pre-Application (Letter of Intent): September 14, 2022
Application: October 5, 2022

Link to Full Announcement: https://cdmrp.army.mil/funding/mrp

 

DoD FY22 Chronic Pain Management Research Program (CPMRP)

• Clinical Exploration Award (CEA)
• Investigator-Initiated Research Award (IIRA)
• Translational Research Award (TRA)

Pre-Application (Preproposal): July 12, 2022
Application: October 13, 2022

Link to Full Announcement: https://cdmrp.army.mil/funding/cpmrp

 

DoD FY22 Lupus Research Program (LRP)

• Idea Award (IA)
• Impact Award (IPA)
• Transformative Vision Award (TVA)

Pre-Application (Letter of Intent): August 16, 2022
Application: September 1, 2022

Link to Full Announcement: https://cdmrp.army.mil/funding/lrp

 

DoD FY22 Vision Research Program (VRP)

• Clinical Trial Award (CTA)
• Focused Translational Team Science Award (FTTSA)
• Investigator-Initiated Research Award (IIRA)
• Translational Research Award (TRA)

Pre-Application (Preproposal): July 15, 2022
Application: November 9, 2022

Link to Full Announcement: https://cdmrp.army.mil/funding/vrp

 

DoD FY22 Rare Cancers Research Program (RCRP)

• Concept Award (CA)
• Idea Development Award (IDA)
• Resource and Community Development Award (RCDA)

Pre-Application (Letter of Intent): July 18, 2022
Application: August 29, 2022

Link to Full Announcement: https://cdmrp.army.mil/funding/rcrp

 

DoD FY22 Pancreatic Cancer Research Program (PCARP)

• Idea Development Award (IDA)
• Translational Research Partnership Award (TRPA)

Pre-Application (Preproposal): July 8, 2022  
Application: October 6, 2022

Link to Full Announcement: https://cdmrp.army.mil/funding/pcarp

 

DoD FY22 Multiple Sclerosis Research Program (MSRP)

• Clinical Trial Award (CTA)
• Early Investigator Research Award (EIRA)
• Exploration - Hypothesis Development Award (EHDA)
• Investigator-Initiated Research Award (IIRA)

Pre-Application (Preproposal): June 23, 2022

Application: October 3, 2022

Link to Full Announcement: https://cdmrp.army.mil/funding/msrp

 

DoD FY22 Bone Marrow Failure Research Program (BMFRP)

• Idea Development Award (IDA)
• Investigator-Initiated Research Award (IIRA)

Pre-Application (Preproposal): June 29, 2022

Application: September 23, 2022

Link to Full Announcement: https://cdmrp.army.mil/funding/bmfrp

 

DoD FY22 Prostate Cancer Research Program (PCRP)

• Early Investigator Research Award (EIRA)
• Physician Research Award (PRA)

Pre-Application (LOI): July 7, 2022

Application: July 28, 2022

Letters of Recommendation: August 2, 2022

• Translational Science Award (TSA)
• Health Disparity Research Award (HDRA)
• Data Science Award (DSA)

Pre-Application (LOI): August 4, 2022

Application: August 25, 2022

• Idea Development Award (IDA)

Pre-Application (LOI): July 7, 2022

Application: July 28, 2022

Link to Full Announcement: https://cdmrp.army.mil/funding/pcrp

 

DoD FY22 Peer Reviewed Cancer Research Program (PRCRP)

• Behavioral Health Science Award (BHSA)
• Career Development Award (CDA) – Fellow Option
• Career Development Award (CDA) – Virtual Cancer Center Scholar Option
• Translational Team Science Award (TTSA)

Pre-Application (Letter of Intent): July 12, 2022

Application: August 2, 2022

• Convergent Science Cancer Consortium Development Award (CSCCDA)

Pre-Application (Letter of Intent): August 17

Application: September 7, 2022

Link to Full Announcement: https://cdmrp.army.mil/funding/prcrp

 

DoD FY22 Lung Cancer Research Program (LCRP)

• Clinical Translational Research Partnership Award (CTRPA)        

Pre-Application (Letter of Intent): July 13, 2022

Letter of Intent is required.

Application: July 27, 2022

Link to Full Announcement: https://cdmrp.army.mil/funding/lcrp